Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization

J. L. Raoul, B. Sangro, A. Forner, V. Mazzaferro, F. Piscaglia, L. Bolondi, Riccardo Lencioni

Research output: Contribution to journalArticle

306 Citations (Scopus)

Abstract

Transarterial chemoembolization (TACE) is considered the gold standard for treating intermediate-stage hepatocellular carcinoma (HCC). However, intermediate-stage HCC includes a heterogeneous population of patients with varying tumour burdens, liver function (Child-Pugh A or B) and disease aetiology. This suggests that not all patients with intermediate-stage HCC will derive similar benefit from TACE, and that some patients may benefit from other treatment options. Results of an extensive literature review into the treatment of unresectable HCC with TACE were combined with our own clinical experience to identify factors that may predict survival after TACE. We also report contraindications to TACE and propose a treatment algorithm for the repetition of TACE. In addition, we have constructed a number of expert opinions that may be used as a guide to help physicians make treatment decisions for their patients with intermediate-stage HCC. The data included in the literature review related almost exclusively to conventional TACE, rather than to TACE with drug-eluting beads. Therefore, the findings and conclusions of the literature review are only applicable to the treatment of HCC with conventional TACE. Treating physicians may want to consider other treatment options for patients with intermediate-stage HCC who are not suitable for or do not respond to TACE. By distinguishing those patients who represent good candidates for TACE from those where little or no benefit might be expected, it may be possible to make better use of current treatment options and improve outcomes for patients.

Original languageEnglish (US)
Pages (from-to)212-220
Number of pages9
JournalCancer Treatment Reviews
Volume37
Issue number3
DOIs
StatePublished - May 2011
Externally publishedYes

Fingerprint

Expert Testimony
Hepatocellular Carcinoma
Therapeutics
Physicians
Tumor Burden
Survival
Liver
Pharmaceutical Preparations
Population

Keywords

  • Contraindications
  • HCC
  • Hepatocellular carcinoma
  • Intermediate stage
  • Sorafenib
  • TACE
  • Transarterial chemoembolization

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Evolving strategies for the management of intermediate-stage hepatocellular carcinoma : Available evidence and expert opinion on the use of transarterial chemoembolization. / Raoul, J. L.; Sangro, B.; Forner, A.; Mazzaferro, V.; Piscaglia, F.; Bolondi, L.; Lencioni, Riccardo.

In: Cancer Treatment Reviews, Vol. 37, No. 3, 05.2011, p. 212-220.

Research output: Contribution to journalArticle

Raoul, J. L. ; Sangro, B. ; Forner, A. ; Mazzaferro, V. ; Piscaglia, F. ; Bolondi, L. ; Lencioni, Riccardo. / Evolving strategies for the management of intermediate-stage hepatocellular carcinoma : Available evidence and expert opinion on the use of transarterial chemoembolization. In: Cancer Treatment Reviews. 2011 ; Vol. 37, No. 3. pp. 212-220.
@article{b5b4d372e7f8471db22371e6978f9b52,
title = "Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization",
abstract = "Transarterial chemoembolization (TACE) is considered the gold standard for treating intermediate-stage hepatocellular carcinoma (HCC). However, intermediate-stage HCC includes a heterogeneous population of patients with varying tumour burdens, liver function (Child-Pugh A or B) and disease aetiology. This suggests that not all patients with intermediate-stage HCC will derive similar benefit from TACE, and that some patients may benefit from other treatment options. Results of an extensive literature review into the treatment of unresectable HCC with TACE were combined with our own clinical experience to identify factors that may predict survival after TACE. We also report contraindications to TACE and propose a treatment algorithm for the repetition of TACE. In addition, we have constructed a number of expert opinions that may be used as a guide to help physicians make treatment decisions for their patients with intermediate-stage HCC. The data included in the literature review related almost exclusively to conventional TACE, rather than to TACE with drug-eluting beads. Therefore, the findings and conclusions of the literature review are only applicable to the treatment of HCC with conventional TACE. Treating physicians may want to consider other treatment options for patients with intermediate-stage HCC who are not suitable for or do not respond to TACE. By distinguishing those patients who represent good candidates for TACE from those where little or no benefit might be expected, it may be possible to make better use of current treatment options and improve outcomes for patients.",
keywords = "Contraindications, HCC, Hepatocellular carcinoma, Intermediate stage, Sorafenib, TACE, Transarterial chemoembolization",
author = "Raoul, {J. L.} and B. Sangro and A. Forner and V. Mazzaferro and F. Piscaglia and L. Bolondi and Riccardo Lencioni",
year = "2011",
month = "5",
doi = "10.1016/j.ctrv.2010.07.006",
language = "English (US)",
volume = "37",
pages = "212--220",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Evolving strategies for the management of intermediate-stage hepatocellular carcinoma

T2 - Available evidence and expert opinion on the use of transarterial chemoembolization

AU - Raoul, J. L.

AU - Sangro, B.

AU - Forner, A.

AU - Mazzaferro, V.

AU - Piscaglia, F.

AU - Bolondi, L.

AU - Lencioni, Riccardo

PY - 2011/5

Y1 - 2011/5

N2 - Transarterial chemoembolization (TACE) is considered the gold standard for treating intermediate-stage hepatocellular carcinoma (HCC). However, intermediate-stage HCC includes a heterogeneous population of patients with varying tumour burdens, liver function (Child-Pugh A or B) and disease aetiology. This suggests that not all patients with intermediate-stage HCC will derive similar benefit from TACE, and that some patients may benefit from other treatment options. Results of an extensive literature review into the treatment of unresectable HCC with TACE were combined with our own clinical experience to identify factors that may predict survival after TACE. We also report contraindications to TACE and propose a treatment algorithm for the repetition of TACE. In addition, we have constructed a number of expert opinions that may be used as a guide to help physicians make treatment decisions for their patients with intermediate-stage HCC. The data included in the literature review related almost exclusively to conventional TACE, rather than to TACE with drug-eluting beads. Therefore, the findings and conclusions of the literature review are only applicable to the treatment of HCC with conventional TACE. Treating physicians may want to consider other treatment options for patients with intermediate-stage HCC who are not suitable for or do not respond to TACE. By distinguishing those patients who represent good candidates for TACE from those where little or no benefit might be expected, it may be possible to make better use of current treatment options and improve outcomes for patients.

AB - Transarterial chemoembolization (TACE) is considered the gold standard for treating intermediate-stage hepatocellular carcinoma (HCC). However, intermediate-stage HCC includes a heterogeneous population of patients with varying tumour burdens, liver function (Child-Pugh A or B) and disease aetiology. This suggests that not all patients with intermediate-stage HCC will derive similar benefit from TACE, and that some patients may benefit from other treatment options. Results of an extensive literature review into the treatment of unresectable HCC with TACE were combined with our own clinical experience to identify factors that may predict survival after TACE. We also report contraindications to TACE and propose a treatment algorithm for the repetition of TACE. In addition, we have constructed a number of expert opinions that may be used as a guide to help physicians make treatment decisions for their patients with intermediate-stage HCC. The data included in the literature review related almost exclusively to conventional TACE, rather than to TACE with drug-eluting beads. Therefore, the findings and conclusions of the literature review are only applicable to the treatment of HCC with conventional TACE. Treating physicians may want to consider other treatment options for patients with intermediate-stage HCC who are not suitable for or do not respond to TACE. By distinguishing those patients who represent good candidates for TACE from those where little or no benefit might be expected, it may be possible to make better use of current treatment options and improve outcomes for patients.

KW - Contraindications

KW - HCC

KW - Hepatocellular carcinoma

KW - Intermediate stage

KW - Sorafenib

KW - TACE

KW - Transarterial chemoembolization

UR - http://www.scopus.com/inward/record.url?scp=79952039170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952039170&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2010.07.006

DO - 10.1016/j.ctrv.2010.07.006

M3 - Article

C2 - 20724077

AN - SCOPUS:79952039170

VL - 37

SP - 212

EP - 220

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 3

ER -